Extracorporeal cell therapy with granulocytes in a pig model of Gram-positive sepsis

Critical Care Medicine

Volumn 37, Issue 2, 2009, Pages 606-613

  Sauer, Martin ^a   Altrichter, Jens ^a   Kreutzer, Hans J ^a   Lögters, Tim ^b   Scholz, Martin ^b   Nöldge Schomburg, Gabriele ^a   Schmidt, Reinhard ^a   Mitzner, Steffen R ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Bioreactors; Extracorporeal circulation; HL 60 cells; Neutrophils; Plasmapheresis; Sepsis

Indexed keywords

CYTOKINE; LACTIC ACID;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BIOREACTOR; BLOOD CELL COUNT; BLOOD GAS; CELL DIFFERENTIATION; CONTROLLED STUDY; EXPERIMENTAL PIG; EXTRACORPOREAL CIRCULATION; FEMALE; GRAM POSITIVE INFECTION; GRANULOCYTE TRANSFUSION; HUMAN; HUMAN CELL; LETHAL DOSE; NONHUMAN; OBSERVATION; PRIORITY JOURNAL; SEPSIS; STAPHYLOCOCCUS AUREUS; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; GRANULOCYTES; HL-60 CELLS; HUMANS; PLASMAPHERESIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SEPSIS; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS; SWINE;

EID: 67650398303     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318194aa77     Document Type: Article

References (42)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
2. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30:536-555
3. Rivers E, Nguyen B, Havstad S, et al: Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
4. Kreymann KG, de Heer G, Nierhaus A, et al: Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007; 35:2677-2685
5. Nasraway SA: The problems and challenges of immunotherapy in sepsis. Chest 2003; 123(Suppl 5):451S-459S
6. Bochud PY, Calandra T: Pathogenesis of sepsis: New concepts and implications for future treatment. BMJ 2003; 326:262-266
7. Docke WD, Randow F, Syrbe U, et al: Mono-cyte deactivation in septic patients: Restoration by IFN-gamma treatment. Nat Med 1997; 3:678-681
8. Caille V, Chiche JD, Nciri N, et al: Histocompatibility leukocyte antigen-D related expression is specifically altered and predicts mortality in septic shock but not in other causes of shock. Shock 2004; 22:521-526
9. Kaufmann I, Hoelzl A, Schliephake F, et al: Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing sepsis severity. Shock 2006; 26:254-261
10. Liles WC: Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases. Semin Respir Infect 2001; 16:11-17
11. Flohe S, Lendemans S, Selbach C, et al: Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma. Crit Care Med 2003; 31:2462-2469
12. Stephens DP, Thomas JH, Dip G, et al: Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit Care Med 2008; 36:448-454
13. Hubel K, Dale DC, Liles WC: Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: Current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis 2002; 185:1490-1501
14. Carr R, Modi N, Dore C: G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003; (3): CD003066
15. Napolitano LM: Immune stimulation in sepsis: To be or not to be? Chest 2005; 127:1882-1885
16. Murphey ED, Sherwood ER: Bacterial clearance and mortality are not improved by a combination of IL-10 neutralization and IFN-gamma administration in a murine model of post-CLP immunosuppression. Shock 2006; 26:417-424
17. Karzai W, Cui X, Heinicke N, et al: Neutrophil stimulation with granulocyte colony-stimulating factor worsens ventilator-induced lung injury and mortality in rats. Anesthesiology 2005; 103:996-1005
18. Moraes TJ, Zurawska JH, Downey GP: Neutrophil granule contents in the pathogenesis of lung injury. Curr Opin Hematol 2006; 13:21-27
19. Hoesel LM, Neff TA, Neff SB, et al: Harmful and protective roles of neutrophils in sepsis. Shock 2005; 24:40-47
20. Scholz M, Cinatl J, Schadel-Hopfner M, et al: Neutrophils and the blood-brain barrier dysfunction after trauma. Med Res Rev 2007; 27:401-416
21. Mohan P, Brocklehurst P: Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. Cochrane Database Syst Rev 2003; (4):CD003956
22. Briones MA, Josephson CD, Hillyer CD: Granulocyte transfusion: Revisited. Curr Hematol Rep 2003; 2:522-527
23. Stanworth SJ, Massey E, Hyde C, et al: Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2005 (3):CD005339
24. Safdar A, Hanna HA, Boktour M, et al: Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: Retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101:2859-2865
25. Taylor RW, O'Brien J, Trottier SJ, et al: Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med 2006; 34:2302-2308
26. Blajchman MA: The clinical benefits of the leukoreduction of blood products. J Trauma 2006; 60(Suppl 6):S83-S90
27. Bilgin YM, van de Watering LM, Eijsman L, et al: Is increased mortality associated with post-operative infections after leukocytes containing red blood cell transfusions in cardiac surgery? An extended analysis. Transfus Med 2007; 17:304-311
28. Mitzner SR, Freytag J, Sauer M, et al: Use of human preconditioned phagocytes for extra-corporeal immune support: Introduction of a concept. Ther Apher 2001; 5:423-432
29. Lee PA, Weger GW, Pryor RW, et al: Effects of filter pore size on efficacy of continuous arterio-venous hemofiltration therapy for Staphylococcus aureus-induced septicaemia in immature swine. Crit Care Med 1998; 26:730 -737
30. Lee PA, Matson JR, Pryor RW, et al: Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1993 21:914 -924
31. Hinshaw LB, Taylor FB, Chang ACK, et al: Staphylococcus aureus-induced shock: A pathophysiologic study. Circ Shock 1988; 26:257-265
32. Ronco C, Inguaggiato P, D'Intini V, et al: The role of extracorporeal therapies in sepsis. J Nephrol 2003; 16(Suppl 7):S34-S41
33. Bellomo R, Honoré PM, Matson J, et al: Extracor-poreal blood treatment (EBT) methods in SIRS/ Sepsis. Int J Artif Organs 2005; 28:450 - 458
34. Carlet J: Immunological therapy in sepsis: Currently available. Intensive Care Med 2001; 27:93-103
35. Cole L, Bellomo R, Hart G, et al: A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30:100-106
36. Busund R, Koukline V, Utrobin U, et al: Plasmapheresis in severe sepsis and septic shock: A prospective, randomised, controlled trial. Intensive Care Med 2002; 28:1434-1439
37. Stegmayr BG, Banga R, Berggren L, et al: Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. Crit Care Med 2003; 31:1730-1736
38. Ronco C, Brendolan A, Lonnemann G, et al: A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002; 30:1250-1255
39. Tetta C, Bellomo R, Ronco C: Artificial organ treatment for multiple organ failure, acute renal failure, and sepsis: Recent new trends. Artif Organs 2003; 27:202-213
40. Allen JW, Hassanein T, Bhatia SN: Advances in bioartificial liver devices. Hepatology 2001; 34:447-455
41. Strain AJ, Neuberger JM: A bioartificial liver - state of the art. Science 2002; 295:1005-1009
42. Demetriou AA, Brown RS Jr, Busuttil RW, et al: Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239: 660-667 43. Humes HD, Weitzel WF, Bartlett RH, et al: Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 2004; 66: 1578-1588